Larotrectinib Drug Approved For Treatment Of Cancers With Specific Gene Mutation Approved

by Colleen Fleiss on  July 28, 2019 at 8:29 PM Cancer News
RSS Email Print This Page Comment bookmark
Font : A-A+

Treating patients with Vitrakvi (larotrectinib) is recommended for patients whose disease has spread or cannot be surgically removed, and who have no other satisfactory treatment options, stated new study.
Larotrectinib Drug Approved For Treatment Of Cancers With Specific Gene Mutation Approved
Larotrectinib Drug Approved For Treatment Of Cancers With Specific Gene Mutation Approved

Vitrakvi is the first so-called 'histology-independent' cancer treatment recommended for approval in the EU. This means that it can be used to treat non-haematological (i.e. that do not begin in the blood or bone marrow) tumours with this specific mutation, regardless of where in the body the tumour originated. Before patients can be started on the medicine, the presence of the mutation in the tumour should be confirmed by a validated test.

Show Full Article


The active substance in Vitrakvi - larotrectinib - targets a very specific genomic alteration of a patient's tumour. This occurs when NTRK genes that encode specific proteins are abnormally fused to a gene. This mutation, called NTRK gene fusion, leads to the development of proteins that can cause cancer cells to grow. Vitrakvi blocks the action of these proteins and in doing so inhibits the growth of the cancer.

NTRK gene fusions can be observed very frequently in a certain number of rare cancer types that affect both adults and children. In addition, this gene fusion occurs rarely in some of the most common cancer types.

The efficacy and safety of Vitrakvi were studied in three single-arm trials (i.e. studies with no control group) that included a total of 102 adults and children with cancer that were evaluated. These patients had either already received standard therapy, or would have had to undergo disfiguring surgery, or were unlikely to respond to available therapies.

The share of patients who responded to treatment with Vitrakvi was 67%. Of those, the response lasted six months or longer in 88% and 12 months or longer in 75%. Tumour responses were seen both in rare tumour types such as infantile fibrosarcoma and salivary gland tumours, as well as in common diseases such as lung and colon cancer.

The most common side effects were tiredness, increased levels of liver enzymes, dizziness, constipation, nausea, anaemia (low red blood cell count), and vomiting.

The CHMP recommended a conditional approval for this medicine. This is one of the EU's regulatory mechanisms to facilitate early access to medicines that fulfil an unmet medical need. This type of approval allows the Agency to recommend a medicine for marketing authorisation with less complete data than normally expected, in cases where the benefit of a medicine's immediate availability to patients outweighs the risk inherent in the fact that not all the data are yet available.

The opinion adopted by the CHMP is an intermediary step on Vitrakvi's path to patient access. The opinion will now be sent to the European Commission for the adoption of a decision on an EU-wide marketing authorisation. Once the marketing authorisation has been granted, decisions about price and reimbursement will take place at the level of each Member State, taking into account the potential role/use of this medicine in the context of the national health system of that country.

Source: Medindia

Post a Comment

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
Notify me when reply is posted
I agree to the terms and conditions

Recommended Reading

More News on:

DNA Finger Printing Drug Toxicity Signature Drug Toxicity Cystic Fibrosis Drugs Banned in India McArdle Disease Weaver Syndrome Inherited Breast Cancer Syndromes Von Hippel-Lindau Disease / Rare Genetic Disorder 

News A - Z

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

News Search

Medindia Newsletters

Subscribe to our Free Newsletters!

Terms & Conditions and Privacy Policy.

Stay Connected

  • Available on the Android Market
  • Available on the App Store

News Category

News Archive